title: Impact of urinary FSH price: a cost-effectiveness analysis of recombinant and urinary FSH in assisted reproduction techniques in the USA.
abstract: This study compares the cost-effectiveness of recombinant human FSH (r(h)FSH, Gonal-F) and urinary FSH (uFSH) in assisted reproduction techniques in the USA, using several hypothetical prices for uFSH. A specifically designed Markov model and Monte-Carlo simulation techniques were used to model the possible outcomes during three treatment cycles. Data included in the model were derived from randomized clinical trials and databases. An expert panel determined probability distributions for each decision point throughout each virtual treatment cycle. The assumed unit cost of r(h)FSH was $58.52 (based on the average retail cost) and three unit prices ($49, $45, $40) were used for uFSH. A total of 5000 simulations was performed on a virtual cohort of 100,000 patients. The mean number of assisted reproduction treatment cycles/success (ongoing pregnancy at 12 weeks) was 4.34 with r(h)FSH and 4.75 with uFSH. The total number of pregnancies achieved was 40,665 and 37,890, respectively. The mean cost per successful pregnancy with r(h)FSH was $40 688. For uFSH at unit costs of $40, $45 and $49, the mean costs per successful pregnancy were $43,500, $44,400 and $45,000, respectively (each P < 0.0001 versus r(h)FSH). Thus, despite its greater cost per unit dose, r(h)FSH is more cost-effective than uFSH over a wide range of uFSH prices, reflecting the greater clinical efficacy of r(h)FSH.
authors.affiliation: Texas Fertility Centre, Austin, TX, USA. kaylen@costdoctor.com
authors.forename: K
authors.initials: K
authors.lastname: Silverberg
authors.forename: J
authors.initials: J
authors.lastname: Schertz
authors.forename: B
authors.initials: B
authors.lastname: Falk
authors.forename: A
authors.initials: A
authors.lastname: Beresniak
mesh_terms: D003362:Cost-Benefit Analysis; D005260:Female; D005640:Follicle Stimulating Hormone / Q000191:economics* / Q000627:therapeutic use / Q000652:urine*; D006801:Humans; D007246:Infertility / Q000191:economics / Q000628:therapy; D008297:Male; D008390:Markov Chains; D018803:Models, Economic; D009010:Monte Carlo Method; D011247:Pregnancy; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D027724:Reproductive Techniques, Assisted / Q000191:economics*; D014481:United States
chemical_list: D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone